Condensed Combined Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
Revenue	$ 139	$ 165
Operating expenses:
Research and development (including amounts with related parties)	41,128	27,374
Selling, general and administrative (including amounts with related parties)	45,275	9,493
Total operating expenses	86,403	36,867
Loss from operations	(86,264)	(36,702)
Other income (expense):
Interest and investment income, net	8,944	78
Interest expense (including amounts with related parties)	(3,168)	(1,889)
Other income, net (including amounts with related parties)	13	1,104
Total other income (expense)	5,789	(707)
Loss before income taxes and noncontrolling interests	(80,475)	(37,409)
Income tax expense	(6)	(18)
Net loss	(80,481)	(37,427)
Net loss attributable to noncontrolling interests, net of tax	(867)	(389)
Net loss attributable to ImmunityBio common stockholders	$ (79,614)	$ (37,038)
Net loss per ImmunityBio common share – basic and diluted	$ (0.21)	$ (0.10)
Weighted-average number of common shares used in computing net loss per share – basic and diluted	382,741,464	371,989,232